MiMedx Group, Inc (NASDAQ:MDXG) Receives $9.50 Average Target Price from Analysts

MiMedx Group, Inc (NASDAQ:MDXG) has been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $9.60.

A number of research analysts have weighed in on MDXG shares. Mizuho decreased their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Cantor Fitzgerald reduced their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. UBS Group set a $10.00 price target on MiMedx Group in a research report on Monday, February 23rd. Lake Street Capital cut their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Finally, Citizens Jmp initiated coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating and a $10.00 target price for the company.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $4.89 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. The stock has a market capitalization of $726.51 million, a price-to-earnings ratio of 15.28 and a beta of 1.60. The firm’s 50 day simple moving average is $5.70 and its 200-day simple moving average is $6.57. MiMedx Group has a 12 month low of $4.78 and a 12 month high of $8.46.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. Analysts expect that MiMedx Group will post 0.3 EPS for the current year.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDXG. Trigran Investments Inc. grew its position in shares of MiMedx Group by 10.4% in the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after purchasing an additional 790,901 shares during the period. Vanguard Group Inc. lifted its stake in MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after buying an additional 382,623 shares in the last quarter. State Street Corp boosted its holdings in MiMedx Group by 6.1% in the 4th quarter. State Street Corp now owns 3,813,796 shares of the company’s stock worth $25,819,000 after buying an additional 219,190 shares during the last quarter. First Light Asset Management LLC boosted its holdings in MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after buying an additional 1,725,458 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in MiMedx Group by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company’s stock worth $16,786,000 after buying an additional 97,036 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.